A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1Since this is a Phase 1 trial primarily designed to study safety and find the right dose of CC-97540 rather than prove it works, what does that mean for weighing the potential risks against the possible benefits for my specific condition?
2. 2The trial is listed as 'active not recruiting,' which means they're no longer enrolling new participants — so is there any chance I could still access this treatment, perhaps through a compassionate use program or a future Phase 2 study that might follow this one?
3. 3CAR T cell therapy involves intensive preparation including chemotherapy to condition the immune system before the infusion — given my current health and the severity of my autoimmune disease, am I strong enough to handle that kind of treatment process?
4. 4The trial is tracking serious adverse events and dose-limiting toxicities specifically for each condition like lupus, myositis, systemic sclerosis, and rheumatoid arthritis — based on what's emerged so far from this study, what safety signals are most relevant to my particular diagnosis?
5. 5Before considering an experimental CAR T cell approach like this, are there any standard or recently approved treatments I haven't tried yet that might offer a meaningful benefit with a better-understood safety profile?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.